ArticleAnnals of general psychiatry2025
Effect of lacticaseibacillus paracasei PS23 on anxiety and sleep difficulties among office workers: a double-blind, randomized controlled pilot trial.
Article in Annals of general psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05826704 (Exploring the Effects of Lactobacillus Paracasei PS23 on Workplace-related Stress Symptoms Among Office Workers), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploring the Effects of Lactobacillus Paracasei PS23 on Workplace-related Stress Symptoms Among Office Workers
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOver the past decade, sleep disturbances and stress have markedly increased within the general population. Conditions such as insomnia and poor stress management are linked to a range of physical and psychological symptoms, including cardiovascular diseases, sleep disorders, depression, or anxiety. Recent studies have shown that heat-treated Lacticaseibacillus paracasei PS23 (PS23) can alleviate anxiety in clinical nurses experiencing high stress. However, the potential benefits of live PS23- particularly its effects on sleep quality, anxiety, and stress- remain unexplored.
methodsThis study recruited office workers aged 20-65 years who reported moderate to high levels of perceived stress. Participants in the intervention group received a daily dose of 20 billion colony-forming units of live PS23 for six weeks, while the control group received two placebo capsules containing microcrystalline cellulose powder. Outcomes were assessed at baseline and at the end of the trial, including measures of stress, anxiety, sleep quality, fatigue, activity levels, depression, and overall quality of life. Additionally, changes in salivary stress markers and antioxidant levels were evaluated.
resultsOf the 50 eligible participants initially enrolled, 45 completed the six-week trial with high compliance (> 80%), including 24 in the PS23 group and 21 in the placebo group. Compared to the placebo group, the PS23 group showed statistically significant improvements in overall insomnia symptoms (group × time interaction, p = 0.011), sleep latency (p = 0.045), sleep maintenance (p = 0.002), and trait anxiety levels (group × time interaction, p = 0.044).
conclusionThis pilot randomized controlled trial suggests that live L. paracasei PS23 may offer meaningful improvements in sleep quality and anxiety reduction among office workers experiencing elevated stress levels. REGISTRATION: ClinicalTrials.gov Identifier: NCT05826704; registration date: 4/11/2023. Exploring the Effects of Lactobacillus paracasei PS23 on Workplace-related Stress Symptoms Among Office Workers; URL: https://clinicaltrials.gov/study/NCT05826704.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.